arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Crinetics Pharmaceuticals, Inc.

CRNX Health Care Biotechnology: Pharmaceutical Preparations
$84.95
0.0% Today
as of Oct 23, 16:47 ET
Open
$84.96
High
$85.01
Low
$84.92
Volume
$8M
Avg Vol
$8M
Mkt Cap
$9.0B
P/E (TTM)
—
Beta
—
52w High
$85.01
52w Low
$32.30
Div Yield
—
Shares Out
$106M

Recent Press Releases & News last 60 days · 3 items

Sep 1 · 15:07 InvestorsHub
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
Sep 1 · 13:51 MT Newswires
Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition
Sep 1 · 13:03 PR Business Wire
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

CRNX earnings at a glance

The options market is pricing a move of about ±0.5% after the report, a range of roughly $84.55 to $85.35 from today's $84.95. Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±4.2% on average; after the most recent report on May 7, 2026 it moved +4.3%. That means options currently expect less movement than CRNX has typically delivered. CRNX beat the consensus EPS estimate in 0 of its last 3 reported quarters. Implied volatility is currently 2%. The share price of $84.95 sits near its 52-week high.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$32
$85
100% of range
Avg surprise (last 3)
-4.9%
Avg reaction (last 2)
+4.2%
100% positive
Latest IV / EM
2%
EM ±0.5% · $85 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.38$-1.25$-1.11$-0.98$-0.85 Actual $-0.85Actual $-0.94Actual $-1.01Actual $-0.93Actual $-0.94Actual $-0.96Actual $-1.04Est $-0.99Actual $-1.23Est $-1.13Actual $-1.38Actual $-1.23Est $-1.22Actual $-1.14 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-130M$-91M$-52M$-13M$26M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.14 — — — — financials
Thu May 7, 2026Mar/2026 $-1.23 $-1.22 -0.8% -18.3% +4.3% earnings
Tue Sep 30, 2025Sep 2025 $-1.38 — — — — financials
Thu Aug 7, 2025Jun/2025 $-1.23 $-1.13 -8.8% — — earnings
Thu May 8, 2025Mar/2025 $-1.04 $-0.99 -5.0% — +4.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.96 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.94 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.93 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.01 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.94 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.85 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$25M$11M—$143,000$1M$361,000—$0
Cost of revenue$154,000$200,000——$0$0——
Gross profit————————
Operating income$-132M$-140M—$-143M$-129M$-111M—$-88M
Net income$-121M$-128M—$-130M$-116M$-97M—$-77M
EPS (diluted)$-1.14$-1.23—$-1.38$-1.23$-1.04—$-0.96

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$55M$114M$102M$111M$54M$95M$265M$317M
Inventory$3M$3M$2M—————
Total current assets$1.24B$1.32B$1.05B$1.12B$1.22B$1.29B$1.38B$878M
Total assets$1.32B$1.40B$1.13B$1.20B$1.29B$1.36B$1.43B$937M
Long-term debt————————
Total liabilities$130M$121M$134M$124M$118M$107M$110M$104M
Total equity$1.19B$1.28B$992M$1.07B$1.17B$1.25B$1.32B$833M

Implied volatility — last 90 days

2%55%109%162%216% Jun 07 — IV 76% · EM ±10.5%Jun 08 — IV 63% · EM ±8.3%Jun 09 — IV 61% · EM ±7.6%Jun 10 — IV 65% · EM ±7.7%Jun 11 — IV 90% · EM ±9.9%Jun 12 — IV 98% · EM ±10.0%Jun 15 — IV 151% · EM ±10.9%Jun 19 — IV 60% · EM ±13.2%Jun 22 — IV 50% · EM ±10.4%Jun 23 — IV 53% · EM ±10.9%Jun 24 — IV 53% · EM ±10.7%Jun 25 — IV 61% · EM ±11.9%Jun 26 — IV 57% · EM ±10.9%Jun 29 — IV 63% · EM ±11.2%Jun 30 — IV 74% · EM ±12.7%Jul 01 — IV 55% · EM ±9.2%Jul 02 — IV 57% · EM ±9.3%Jul 03 — IV 58% · EM ±9.1%Jul 06 — IV 216% · EM ±30.0%Jul 07 — IV 24% · EM ±3.2%Jul 08 — IV 25% · EM ±3.2%Jul 09 — IV 30% · EM ±3.5%Jul 10 — IV 29% · EM ±3.2%Jul 13 — IV 31% · EM ±2.6%Jul 14 — IV 34% · EM ±2.4%Jul 16 — IV 56% · EM ±2.3%Jul 20 — IV 9% · EM ±2.1%Jul 21 — IV 9% · EM ±2.1%Jul 22 — IV 15% · EM ±3.5%Jul 23 — IV 11% · EM ±2.5%Jul 28 — IV 10% · EM ±2.0%Jul 29 — IV 12% · EM ±2.4%Jul 30 — IV 12% · EM ±2.4%Aug 10 — IV 18% · EM ±2.4%Aug 24 — IV 2% · EM ±0.5%

Sector peers

AXSM
Axsome Therapeutics, Inc.
$9.1B $145.04-7.2%
CYTK
Cytokinetics, Incorporated
$8.5B $61.23-2.6%
NUVL
Nuvalent, Inc.
$9.8B $123.96
RDY
Dr. Reddy's Laboratories Ltd
$10.2B $13.21+0.1%
IONS
Ionis Pharmaceuticals, Inc.
$7.3B $42.93-3.0%
ALKS
Alkermes plc
$7.0B $43.63+0.3%

CRNX earnings FAQ

What is CRNX's expected move for earnings?

Options currently price a move of about ±0.5%, or $0.40 per share either way from $84.95.

How does CRNX stock usually react to earnings?

Across the last 2 reports the average next-day move was ±4.2%, up 2 times and down 0 times.

What is CRNX's implied volatility?

CRNX's at-the-money implied volatility is about 2% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in